Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine

被引:0
|
作者
Arvanov, VL [1 ]
Wang, RY [1 ]
机构
[1] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Repeated exposure of rats to the psychotomimetic drug phencyclidine (PCP) markedly increased the response of prefrontal cortical neurons to the glutamate agonist N-methyl-D-aspartate (NMDA) relative to agonist alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid. Moreover, acute challenge by PCP produced a significantly reduced block of NMDA-induced current. In addition, the subchronic administration of PCP reduced significantly the paired-pulse facilitation, accompanied by a significant increase of excitatory postsynaptic current variance. These results suggest that repeated exposure to PCP increased evoked release of excitatory amino acids. The enhanced release of excitatory amino acids evoked by NMDA could explain, at least partly, a hypersensitive response to NMDA and a reduced blockade of the NMDA responses by a PCP challenge in rats exposed repeatedly to PCP. Pretreatment with the atypical antipsychotic drug clozapine, but not the typical antipsychotic drug haloperidol, attenuates the repeated PCP-induced effect. Our results support the hypothesis that clozapine may facilitate NMDA receptor-mediated neurotransmission to improve schizophrenic-negative symptoms and cognitive dysfunction. This novel approach is useful for evaluating the cellular mechanisms of action of atypical antipsychotic drugs.
引用
收藏
页码:1000 / 1006
页数:7
相关论文
共 50 条
  • [41] PHENCYCLIDINE RECEPTORS AND N-METHYL-D-ASPARTATE ANTAGONISM - ELECTROPHYSIOLOGIC DATA CORRELATES WITH KNOWN BEHAVIORS
    MARTIN, D
    LODGE, D
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1988, 31 (02) : 279 - 286
  • [42] Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy
    Chartoff, EH
    Ward, RP
    Dorsa, DM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 291 (02): : 531 - 537
  • [43] Inhibition of N-methyl-D-aspartate receptors by haloperidol: Developmental and pharmacological characterization in native and recombinant receptors
    Lynch, DR
    Gallagher, MJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 279 (01): : 154 - 161
  • [44] Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity
    Miyamoto, K
    Nakanishi, H
    Moriguchi, S
    Fukuyama, N
    Eto, K
    Wakamiya, J
    Murao, K
    Arimura, K
    Osame, M
    BRAIN RESEARCH, 2001, 901 (1-2) : 252 - 258
  • [45] Glutamate and schizophrenia:: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions
    Javitt, Daniel C.
    INTEGRATING THE NEUROBIOLOGY OF SCHIZOPHRENIA, 2007, 78 : 69 - +
  • [46] N-METHYL-D-ASPARTATE RECEPTORS MEDIATE RESPONSES OF RAT DORSAL HORN NEURONS TO HINDLIMB ISCHEMIA
    SHER, GD
    MITCHELL, D
    BRAIN RESEARCH, 1990, 522 (01) : 55 - 62
  • [47] N-methyl-D-aspartate receptors contribute to the maintenance of dopaminergic neurons in rat midbrain slice cultures
    Katsuki, H
    Shibata, H
    Takenaka, C
    Kume, T
    Kaneko, S
    Akaike, A
    NEUROSCIENCE LETTERS, 2003, 341 (02) : 123 - 126
  • [48] OXYTOCIN REDUCES THE ACTIVITY OF N-METHYL-D-ASPARTATE RECEPTORS IN CULTURED NEURONS
    CARUSO, S
    ANGELLO, C
    CAMPO, MG
    NICOLETTI, F
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1993, 16 (11) : 921 - 924
  • [49] CALCIUM-DEPENDENT REGULATION OF N-METHYL-D-ASPARTATE RECEPTORS IN RAT HIPPOCAMPAL-NEURONS
    CLARK, GD
    CLIFFORD, DB
    ZORUMSKI, CF
    ANNALS OF NEUROLOGY, 1989, 26 (03) : 443 - 443
  • [50] DESENSITIZATION OF N-METHYL-D-ASPARTATE RECEPTORS IN NEURONS DISSOCIATED FROM ADULT-RAT HIPPOCAMPUS
    ZILBERTER, Y
    UTESHEV, V
    SOKOLOVA, S
    KHODOROV, B
    MOLECULAR PHARMACOLOGY, 1991, 40 (03) : 337 - 341